Dealroom reports Bellus Health acquisition by GSK
GSK acquired Bellus Health for $2 billion to advance camlipixant for refractory chronic cough treatment from the Canadian biopharma.
See the latest news and media coverage for Dealroom. We track all announcements, press releases, and industry mentions in real time, all in one place.
Intelligence platform for startup ecosystems
dealroom.coLast updated
In short: Dealroom reported record 2026 venture capital activity, driven by massive AI rounds and a significant surge in global defense tech.
GSK acquired Bellus Health for $2 billion to advance camlipixant for refractory chronic cough treatment from the Canadian biopharma.
Led by Scaleup Europe Fund and Menlo Ventures, the round nearly doubles the previous $6.6B valuation. Revenue run rate should reach $600M by August; hiring 200+ planned.
Founded by Igor Babuschkin, the startup offers fine-tuning and reinforcement learning tools for open-source AI and has 20 employees. Investors include General Catalyst, NVIDIA, AMD, and Y Combinator.
Valued at $3.4B, the round is led by DFJ Growth, with total funding of $630M to scale Skyhammer and Starhammer.
We partnered with Dealroom to build the 2026 European DeepTech Report.
Dealroom.co, an Amsterdam-based data platform and source of record for startups, high-growth companies, venture capital, and technology ecosystems, today...
UK startups and scaleups secured $9billion in venture capital funding in the third quarter of 2025, the second-highest third-quarter total...
A new list 100 top EMEA tech scaleups puts the emhasis on revenues rather than valuations. Will a focus on earnings attract ...
Track Dealroom and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Dealroom and other trending companies.